A Scottsdale-based bioscience company has developed a test that relies on skin-deep anomalies to detect neurological disorders in the brain including Parkinson’s disease and Lewy body dementia.
CND Life Sciences’ Syn-One Test is already commercially available as a laboratory developed test (LDT), and the company is considering seeking FDA approval for Syn-One to be the first cleared diagnostic tool to detect these neurological conditions in this way.
The National Institutes of Health named the test one of its “Top Promising Medical Findings for 2024” and awarded the company a $3 million grant in 2025.